Fidaxomicin Market Growth Analysis & Regional Outlook Forecasts to 2025
Global Fidaxomicin Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. Fidaxomicin is also termed as Difimicin, or Tiacumicin B, or Lipiarmicin, or Lipiarrmycin, or Lipiarmycin. It is a macrolide antibacterial drug specified for the treatment of Clostridium Difficile-Associated Diarrhea. The antibiotic Fidaxomicin drug kills bacteria in the intestines. Fidaxomicin is the first in a new class of macrocyclic antibiotics and lately been licensed by the European Medicines Agency (EMA). Fidaxomicin is a drug that is not used to treat infections that are not associated to Clostridium difficile. The drug will not work for viral infections, colds, or flu.
★
★
★
★
★
102 views • 4 slides
